Amprenavir's emerging profile is of a highly potent drug, well-tolerated in two-, three-, and four-drug combinations. Among the data being reported that support this view, we direct you to the following key presentations:
A second study being presented describes 1592/amprenavir therapy in the context of other 1592/PI treatment possibilities. Available four week data confirms the rapid and potent antiviral effect of 1592 and amprenavir. Longer term data that demonstrates amprenavir's potency compared with other 1592/PI regimens will be the subject of an oral presentation given by Dr. John Mellors of the University of Pittsburgh Medical Center on Monday, February 2, at 10:30AM. Amprenavir is currently being evaluated in pivotal Phase III clinical trials with development partner Glaxo Wellcome. A U.S. new drug application (NDA) filing is expected later in 1998. An NDA is required for marketing approval.